Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Fish and Richardson
Express Scripts
Daiichi Sankyo
Boehringer Ingelheim

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,129,342

« Back to Dashboard

Summary for Patent: 8,129,342

Title:High purity lipopeptides
Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
Inventor(s): Kelleher; Thomas J. (Thousand Oaks, CA), Lai; Jan-Ji (Westborough, MA), DeCourcey; Joseph P. (Boston, MA), Lynch; Paul D. (Arlington, MA), Zenoni; Maurizio (Ferentino Frosinone, IT), Tagliani; Auro R. (Pavia, IT)
Assignee: Cubist Pharmaceuticals, Inc. (Lexington, MA)
Application Number:12/888,233
Patent Claim Types:
see list of patent claims
Composition; Process; Use; Formulation;

No matches for this query

International Patent Family for Patent: 8,129,342

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria311405► Subscribe
Austria449785► Subscribe
Australia3097801► Subscribe
Australia784937► Subscribe
Brazil0107731► Subscribe
BrazilPI0107731► Subscribe
Canada2398726► Subscribe
Canada2743326► Subscribe
China101240013► Subscribe
China102229650► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus